

# Etiologies for Seizures Around the Time of Vaccination



**WHAT'S KNOWN ON THIS SUBJECT:** Childhood vaccinations mildly increase the risk of febrile seizures in the general pediatric population, during specific risk periods. However, vaccinations are common precipitants for (first) seizures in the genetically determined, fever-sensitive Dravet syndrome (formerly severe myoclonic epilepsy of infancy).



**WHAT THIS STUDY ADDS:** This study shows that in most children with epilepsy onset after vaccination, genetic or structural causes of epilepsy can be identified. This claim includes children with Dravet syndrome (~35%) but also children with benign epilepsy or preexistent encephalopathy.

## abstract



**OBJECTIVES:** This study was an assessment of the incidence, course, and etiology of epilepsy with vaccination-related seizure onset in a population-based cohort of children.

**METHODS:** The medical data of 990 children with seizures after vaccination in the first 2 years of life, reported to the National Institute for Public Health and Environment in the Netherlands in 1997 through 2006, were reviewed. Follow-up data were obtained of children who were subsequently diagnosed with epilepsy and had had seizure onset within 24 hours after administration of an inactivated vaccine or 5 to 12 days after a live attenuated vaccine.

**RESULTS:** Follow-up was available for 23 of 26 children (median age: 10.6 years) with epilepsy onset after vaccination. Twelve children developed epileptic encephalopathy, 8 had benign epilepsy, and 3 had encephalopathy before seizure onset. Underlying causes were identified in 15 children (65%) and included *SCN1A*-related Dravet syndrome (formerly severe myoclonic epilepsy of infancy) or genetic epilepsy with febrile seizures plus syndrome ( $n = 8$  and  $n = 1$ , respectively), a protocadherin 19 mutation, a 1qter microdeletion, neuronal migration disorders ( $n = 2$ ), and other monogenic familial epilepsy ( $n = 2$ ).

**CONCLUSIONS:** Our results suggest that in most cases, genetic or structural defects are the underlying cause of epilepsy with onset after vaccination, including both cases with preexistent encephalopathy or benign epilepsy with good outcome. These results have significant added value in counseling of parents of children with vaccination-related first seizures, and they might help to support public faith in vaccination programs. *Pediatrics* 2014;134:658–666

**AUTHORS:** Nienke E. Verbeek, MD, MSc,<sup>a</sup> Floor E. Jansen, MD, PhD,<sup>b</sup> Patricia E. Vermeer-de Bondt, MD,<sup>c</sup> Carolien G. de Kovel, PhD,<sup>a</sup> Marjan JA. van Kempen, PhD,<sup>a</sup> Dick Lindhout, MD, PhD,<sup>a</sup> Nine VAM. Knoers, MD, PhD,<sup>a</sup> Nicoline A.T. van der Maas, MD,<sup>c</sup> and Eva H. Brilstra, MD, PhD<sup>a</sup>

<sup>a</sup>Department of Medical Genetics, and <sup>b</sup>Rudolph Magnus Institute of Neurosciences, Department of Child Neurology, University Medical Centre Utrecht, Utrecht, Netherlands; and <sup>c</sup>National Institute for Public Health and Environment (RIVM), Bilthoven, Netherlands

### KEY WORDS

Dravet syndrome, epilepsy, etiology, *PCDH19*, *SCN1A*, seizure, vaccination

### ABBREVIATIONS

AEFI—adverse events following immunizations

EEG—electroencephalography

GEFS+—genetic epilepsy with febrile seizures plus

MMR—measles-mumps-rubella

*PCDH19*—protocadherin 19

RIVM—National Institute for Public Health and Environment in the Netherlands

*SCN1A*—neuronal sodium channel 1 subunit gene

Dr Verbeek contributed to the concept and design of the study; collected, interpreted, and analyzed the data; and prepared the first draft of the manuscript. Dr Jansen contributed to interpretation of data and reviewed and revised the manuscript; Dr Vermeer-de Bondt collected data and critically reviewed the manuscript; Mrs de Kovel and van Kempen contributed to data analysis and critically reviewed the manuscript; Dr Lindhout contributed to concept and design of the study and critically reviewed the manuscript; Dr Knoers contributed to analysis of data and critically reviewed the manuscript; Dr van der Maas contributed to concept and design of the study, performed data collection, and reviewed and revised the manuscript; and Dr Brilstra contributed to concept and design of the study, performed data interpretation, and reviewed and revised the manuscript. All authors approved the final manuscript as submitted.

[www.pediatrics.org/cgi/doi/10.1542/peds.2014-0690](http://www.pediatrics.org/cgi/doi/10.1542/peds.2014-0690)

doi:10.1542/peds.2014-0690

Accepted for publication Jul 9, 2014

Address correspondence to Nienke E. Verbeek, MD, MSc, Department of Medical Genetics, Division of Biomedical Genetics, University Medical Centre Utrecht, PO Box 85090, 3508 AB Utrecht, Netherlands. E-mail: n.verbeek@umcutrecht.nl

PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).

Copyright © 2014 by the American Academy of Pediatrics

(Continued on last page)

Parental fear of vaccination-induced neurologic deterioration has led to decreasing vaccination coverage and subsequent outbreaks of preventable infectious diseases in various countries.<sup>1</sup> However, development of neurologic deficits or epileptogenesis could not be related to vaccinations, in several independent epidemiologic studies.<sup>2–6</sup> In the general pediatric population, the risk of febrile seizures is twofold to fivefold increased on the day of administration of an inactivated vaccine and from day 5 up to 2 weeks after administration of a live attenuated vaccine.<sup>2,5–9</sup> A seizure within this risk period might be the first of an epilepsy syndrome, and parents might misinterpret the vaccination as the primary cause of the epilepsy.

In a retrospective study of 14 children with epileptic encephalopathy assumed to be caused by vaccination, 11 had Dravet syndrome due to de novo neuronal sodium channel 1 subunit (*SCN1A*) gene mutations.<sup>10</sup> Dravet syndrome (formerly severe myoclonic epilepsy of infancy) is a rare epilepsy syndrome with seizure onset in the first year of life often triggered by fever, infectious diseases, or vaccinations in a previously healthy child. In the second year, multiple intractable seizure types evolve and neurodevelopment slows.<sup>11</sup> In ~80% of children with Dravet syndrome, a mutation in the *SCN1A* gene is detected.<sup>12</sup> These mutations occur de novo in ~95%.<sup>13,14</sup>

The detection of a pathogenic *SCN1A* mutation in children with alleged vaccination encephalopathy proved that, although the vaccination might have triggered the first seizure, the epilepsy and subsequent intellectual disability were caused by a genetic defect.<sup>10</sup> Most published case series and retrospective cohort studies confirming *SCN1A*-related Dravet syndrome as a cause of alleged vaccination encephalopathy<sup>15–18</sup> have focused on epileptic encephalopathy. Only a few case reports have shown that occasionally other genetic causes of

epilepsy also present with seizures after vaccination.<sup>19,20</sup>

To assess underlying causes in children with any epilepsy syndrome with onset after vaccination, we studied a nationwide 10-year cohort of children reporting possible epileptic seizures after vaccination.

## METHODS

### Selection of the Study Cohort (Stage 1)

We selected a cohort of children ( $N = 1269$ ) with possible epileptic seizures after vaccination in the first 2 years of life, reported to the safety surveillance system of the Dutch National Immunization Program between January 1, 1997, and December 31, 2006.<sup>17,21</sup> This cohort was previously described in detail in a prevalence study of Dravet syndrome that was part of a project on vaccinations and Dravet syndrome approved by the medical ethical committee of the University Medical Centre Utrecht, Utrecht, Netherlands (no. 07/295).<sup>17</sup> Seizures with a temporal relation to vaccination, defined by occurrence within the risk interval of 24 hours after administration of an inactivated vaccine<sup>2</sup> or 5 to 12 days after a live attenuated vaccine (ie, measles-mumps-rubella [MMR] vaccine),<sup>7,22,23</sup> were considered to be vaccination related. Children without vaccination-related seizures were excluded from the present study.

Within the study period, the vaccination schedule in this age group included 4 doses of diphtheria, tetanus, pertussis, inactivated polio vaccine, *Haemophilus influenzae* type b vaccines in the first year of life and 1 dose of MMR vaccine at age 14 months. Additional vaccines were introduced between 2001 and 2006 (Supplemental Tables 4 and 5).<sup>24,25</sup>

### Database of Adverse Events After Immunizations

During the study period, safety surveillance of the national immunization program was performed by the Na-

tional Institute for Public Health and Environment (RIVM) by using an enhanced passive reporting system for adverse events following immunizations (AEFI).<sup>21</sup> AEFIs were reported by either child health clinic staff (~80%), who routinely inquire about adverse events at the next clinic visit after vaccination (according to national guidelines for notification of AEFIs), or by other physicians or parents. The reporting rate of seizures as AEFIs was stable over the years and similar to the incidence rate within an active study.<sup>26</sup> Reported adverse events were registered in a database after extensive supplementation by obtaining detailed eyewitness accounts, medical history from clinic charts, and information from general practitioners.<sup>25</sup> From this database, we extracted the following data: administered vaccine, ages at vaccination, time of reporting of the AEFI and last follow-up, ages at first and last seizure, classification of seizure (s), body temperature at time of seizure (categorized as <37.5, 37.5–38.4, or ≥38.5°C), family history of seizures, and results of genetic, metabolic, and imaging studies.

### Selection of Children With Epilepsy and Vaccination-Related Onset (Stage 2)

From the cohort of vaccination-related seizures, children in whom this reported seizure had been the first seizure, and who had been diagnosed with epilepsy, were selected. The parents of these children were contacted for written consent to retrieve additional data from medical files.

The following additional data were collected: age at last seizure and at last follow-up, types of seizures, response to treatment, results of electroencephalography (EEG), psychomotor development before and after seizure onset, comorbidity, family history, and results of physical examination and genetic, metabolic, and imaging studies.

## Classification of Epilepsy Syndromes

Seizure types, epilepsy syndromes, and etiology were classified by a pediatric neurologist (F.E.J.) and a clinical geneticist (N.E.V.) according to the proposed International League Against Epilepsy classification of 2010 based on data from medical files and EEG reports.<sup>27</sup> Children were further categorized as follows: group I, children with a preexistent encephalopathy, defined as developmental delay preceding the seizure onset; group II, children with epileptic encephalopathy, defined as (temporarily) refractory seizures and developmental decline related to recurrent seizures; and group III, children with relatively benign epilepsy, defined as normal development and good seizure control.

## Statistical Analysis

We compared the characteristics of reported seizures between children with and without epilepsy with vaccination-related onset in our cohort, and between the different subgroups of children with epilepsy. The Mann-Whitney *U* test or Kruskal-Wallis test was used to analyze continuous variables (ie, ages at first vaccination-related seizure, report of event, last follow-up). Binary variables (ie, proportions of types of vaccination [inactivated or live attenuated] and body temperature at the time of seizure [ $<38.5^{\circ}\text{C}$  or  $\geq 38.5^{\circ}\text{C}$ ]) were calculated with either Pearson's  $\chi^2$  test or the Fisher exact test. A threshold of  $\alpha = 0.05$  was considered significant.

## RESULTS

### Baseline Characteristics of Study Cohort

Within the studied 10-year period, 990 children were reported with 1022 possible epileptic seizures occurring in a temporal relation to either an inactivated vaccine ( $n = 695$  [68.0%]) or live attenuated vaccine ( $n = 327$  [32.0%]) administered in the first 2 years of life. The

median age at the end of stage 1 follow-up was 15 months (Table 1). In these 10 years, 1.9 million infants received  $>7.5$  million diphtheria, tetanus, pertussis, inactivated polio vaccine, *Haemophilus influenzae* type b combination vaccines, and 1.8 million toddlers received their first MMR vaccine.

Of the 990 reported children (Fig 1), 45 (4.5%) had been diagnosed with epilepsy during stage 1 follow-up; 26 (2.6%) had vaccination-related seizure onset and 19 (1.9%) had seizure onset before the reported vaccination-related seizure. A total of 945 children had febrile, afebrile, or atypical seizures but were not diagnosed with epilepsy during stage 1 follow-up. In 14 (1.4%) of the 990 children, an underlying etiology related to the seizures or seizure susceptibility had been reported to the RIVM during stage 1 follow-up. Those reports did not include any of the 26 children with epilepsy with vaccination-related onset (Fig 1, Table 2).

The 26 children with epilepsy with vaccination-related onset (median age at epilepsy diagnosis: 11.5 months; age range: 4–41 months) were older at follow-up than the other children (median: 19 vs 15 months;  $P = .009$ ). They more often had subsequent vaccination-related seizures (23.1% vs 2.4% in all other children;  $P < .001$ ) and more often had body temperatures  $<38.5^{\circ}\text{C}$  during the reported seizures (54.8% vs 20.8%;  $\chi^2$  test,  $P < .001$ ) (Table 1).

### Follow-up of Children With Epilepsy and Vaccination-Related Onset

Parents of 23 (88%) of the 26 children with epilepsy with vaccination-related onset provided informed consent for retrieval of extended follow-up (stage 2) information from medical files. There were no significant differences in baseline characteristics between children with and without extended follow-up (data not shown). The median age at this extended follow-up was 10.6 years

(range: 5.6–23.6 years). Genetic testing was performed in 14 (61%) of 23 children. Clinical characteristics and results of ancillary investigations are summarized in Table 3.

### Group I: Presumed Preexistent Encephalopathy

Three (13%) of the 23 children with vaccination-related epilepsy onset already had developmental delay before seizure onset and developed mild to severe intellectual disability. They were therefore presumed to have preexistent encephalopathy. They developed feversensitive epilepsy with focal seizures and had abnormal results on brain MRI scans. One child (case 1) had a terminal microdeletion of chromosome 1q and the second child (case 2) had bilateral periventricular nodular heterotopias without a *FLNA*-mutation detected by using DNA sequencing. Both children had additional multiple congenital malformations and dysmorphic features. In the third child, a distinct developmental delay preceded the seizure onset, but genetic analyses had not been performed.

### Group II: Epileptic Encephalopathy

Twelve (52%) of the 23 children with vaccination-related epilepsy onset were considered to have epileptic encephalopathy. All but 2 had intractable seizures. In 10 of the 12 children, an underlying cause was determined. Eight children (cases 4–11) were diagnosed with Dravet syndrome (previously described<sup>17</sup>) and had a pathogenic *SCN1A* mutation. One girl (case 12) had epilepsy and mental retardation restricted to female subjects and a de novo protocadherin 19 (*PCDH19*) mutation (described as case 7 in van Harssel et al<sup>28</sup>). One child (case 13) died unexpectedly at age 19 months. Postmortal microscopic examination of brain tissue showed a bilateral perisylvian neuronal migration disorder. Genetic analyses, performed with DNA

**TABLE 1** Baseline Characteristics of Children With Vaccination-Related Seizures, With or Without Vaccination-Related Epilepsy Onset

| Characteristics of Reports                            | All Children (n = 990)                      |                          | P      | Children With Vaccination-Related Epilepsy Onset and Stage 2 Follow-up (n = 23) |   | P                 | Total No. |
|---|---|--------------------------|--------|---|---|-------------------|-----------|
|   | Vaccination-Related Epilepsy Onset (n = 26) | Other Children (n = 964) |        | Group I: Presumed Preexistent Encephalopathy (n = 3)                            | Group II: Epileptic Encephalopathy (n = 12) |                   |           |
| Median age, mo (range), at first reported vaccination | 5.6 (2.2–16.2)                              | 11.6 (0.2–22.2)          | .154   | 6.4 (5.6–15.1)  | 4.7 (2.3–12.1)                              | .005              | 23        |
| Report of seizure to safety surveillance system       | 10.8 (4.3–166)                              | 14.2 (0.3–73.4)          | .860   | 11.9 (5.7–19.9)   | 6.9 (4.3–166)                               | .171              | 23        |
| End of stage 1 follow-up                              | 19 (7–166)                                  | 15 (0–105)               | .009   | 18 (13–21)  | 19 (9–166)                                  | .847              | 23        |
| Number of children with male gender, (%)              | 11 (42.3)                                   | 509 (52.8)               | .290   | 1 (33.3)  | 5 (41.7)                                    | .685 <sup>a</sup> | 23        |
| Multiple reports of seizures after vaccinations, (%)  | 6 (23.1)                                    | 23 (2.4%)                | <.001  | 1 (33.3)  | 4 (33.3)                                    | .369 <sup>a</sup> | 23        |
| Number of reported seizures                           | 33  | 989                      |        | 4   | 17  |                   | 30        |
| Inactivated vaccine (versus attenuated vaccine, %)    | 27 (81.8)                                   | 668 (67.5)               | .090   | 3 (75)  | 17 (100)                                    | .019 <sup>a</sup> | 30        |
| Temperature <38.5°C, (%)                              | 17 (54.8)                                   | 193 (20.8)               | <.001* | 3 (75)  | 10 (66.7)                                   | .114 <sup>a</sup> | 28        |

\*  $P = .001$  for inactivated vaccines and  $P = .018$  for live attenuated vaccines;  $P = .025$  for inactivated vaccines, when known Dravet syndrome was excluded.

<sup>a</sup> Fisher exact test, group III versus groups I and II.

extracted from postmortal tissue, failed.


One child (case 14) had fever-sensitive epilepsy, which was drug resistant in infancy but relatively well controlled later on. Results of extensive metabolic and molecular testing, including analysis of the *SCN1A* and the *PCDH19* gene and testing for Angelman syndrome, did not reveal an underlying cause. The last child (case 15) was diagnosed with West syndrome, which later developed into Lennox-Gastaut syndrome. Extensive metabolic and genetic analyses, including analysis of the *SCN1A* gene, did not reveal an underlying cause.

### Group III: Benign Epilepsy

Eight (35%) of the 23 children with vaccination-related epilepsy onset were considered to have relatively benign epilepsy. Seven of the 8 children were seizure-free without use of antiepileptic drugs at follow-up. The median age at last seizure was 4 years (range: 1.3–8.5 years). An underlying genetic etiology was identified or was plausible on the basis of the family history in 3 of the 8 children.

Five of the 8 children had fever-sensitive epilepsy classified as febrile seizures plus (cases 16 and 19–22). In 3 children, a (grand)parent had had febrile seizures as well, consistent with a diagnosis of genetic epilepsy with febrile seizure plus (GEFS+) syndrome. In only 1 of those 5 children had genetic testing been performed (case 16). In this child, DNA-analysis of the *SCN1A* gene showed a pathogenic mutation, inherited from her affected father (previously described<sup>29</sup>).

The 3 other children had epilepsy without fever sensitivity (cases 17, 18, and 23). Two of these 3 children (cases 17 and 18) had multiple, similarly affected family members and were either diagnosed with benign familial infantile epilepsy or unclassified familial epilepsy (Fig 2). Both



**FIGURE 1** Design of study and overview of results. <sup>a</sup>See Table 2. <sup>b</sup>See Table 3.

pedigrees were compatible with autosomal dominant inherited epilepsies, but neither family opted for genetic testing. Case 17 had mild learning problems, as did several other family members with and without epilepsy. The clinical history and EEG results were not compatible with a diagnosis of epileptic encephalopathy. Case 23 had unclassified epilepsy with a negative family history for seizures.

### Differences in Characteristics Between Subgroups of Children With Epilepsy Who Had Vaccination-Related Onset

In children with presumed preexistent (group I) or epileptic (group II) encephalopathy, seizures occurred more often after administration of inactivated vaccines (75% and 100%, respectively) and started at younger ages (median: 6.4 and 4.7 months)

than in children with benign epilepsy (group III: 55.6% [ $P = .019$ , Fisher exact test for group I/II versus group III], and 13.6 months [ $P = .005$ , Kruskal-Wallis test]). There were no statistically significant differences between the 3 subgroups in body temperature at the time of seizure, delay between seizure and time of report, or age at original follow-up by the RIVM (Table 1).

## DISCUSSION

In this Dutch, nationwide, 10-year cohort of children reported with possible epileptic seizures in a time frame related to a vaccination, 26 children (2.6%) were identified in whom the reported seizure was the first of an epilepsy syndrome. Extended follow-up of 23 of these children found that 12 had developed epileptic encephalopathy, 3 had preexisting encephalopathy, and 8 had well-controlled epilepsy with normal cognitive outcome.

Underlying causes of the epilepsy syndromes were detected in two-thirds of children, were genetic in the majority of these children, and were likely genetic in 2 additional cases because of the presence of cortical malformations, dysmorphic features, and other congenital anomalies.

**TABLE 2** Underlying Causes of Seizures Related to Vaccination, Reported at Stage 1 Follow-up (14 of 990 Children)

| Type of Etiology According to ILAE 2010                        | Etiology   | Type of Seizures                | Gender | Vaccination | Age at Vaccination (mon) |
|--|--|---------------------------------|--------|-------------|--------------------------|
| Children with vaccination-related seizure onset                |  |                                 |        |             |                          |
| Genetic  | Sotos syndrome   | Multiple simple FS              | Male   | MMR         | 15.5                     |
| Genetic  | Down syndrome  | Atypical seizure                | Male   | dh1         | 3.0                      |
| Genetic  | Down syndrome  | Atypical seizure                | Male   | dh3         | 6.9                      |
| Genetic  | Wolf-Hirschhorn syndrome                                       | Simple FS                       | Male   | MMR         | 14.8                     |
| Structural   | Dandy-Walker cyst and congenital hydrocephalus                 | Simple FS                       | Male   | dh4         | 21.5                     |
| Acute symptomatic  | Acute arterial media infarct due to thrombus in cardiomyopathy | Afebrile, focal seizure         | Female | dh2         | 3.7                      |
| Acute symptomatic  | Human herpesvirus 6 infection                                  | Complex FS                      | Female | MC          | 14.6                     |
| Acute symptomatic  | Invagination   | Atypical seizure, not epileptic | Female | MC          | 15.5                     |
| Children with seizure onset before vaccination-related seizure |  |                                 |        |             |                          |
| Genetic  | GEFS+ syndrome due to <i>SCN1A</i> mutation                    | Multiple complex FS             | Female | MC          | 15.4                     |
| Structural   | Perinatal intracerebral hemorrhage                             | Epilepsy                        | Male   | dh3         | 5.3                      |
| Structural   | Congenital toxoplasmosis infection                             | Epilepsy                        | Female | dh3         | 6.5                      |
| Structural   | Perinatal intracerebral hemorrhage                             | Epilepsy                        | Male   | dh3         | 6.8                      |
| Structural   | Pyridoxine-dependent epilepsy                                  | Epilepsy                        | Female | dh4         | 11.1                     |
| Structural   | Previous stroke  | Multiple simple FS              | Male   | d4          | 16.3                     |

dh, dtp-ipv(-)hib vaccine; FS, febrile seizure; ILAE, International League Against Epilepsy; MC, MMR and meningitis C vaccine.

In children with identified genetic causes, these fully explained the electroclinical syndromes and other clinical features. Although no underlying cause was detected in one-third of children with epilepsy with vaccination-related onset, a genetic basis of epilepsy in these children is still possible: genetic analyses were incomplete, some children had positive family histories for seizures, and molecular defects underlying many genetically determined epilepsies have yet to be discovered. In the past, the absence of a detectable underlying cause in children with vaccination-related seizure onset led to the assumption that the vaccination itself was the cause of the subsequent neurologic deterioration in some. However, the large variability in electroclinical syndromes and corresponding cognitive outcomes in our study further support the hypothesis that predisposing factors within the child, and not the vaccination, cause the observed neurologic deterioration.<sup>10</sup>

The administered vaccines could have acted as a trigger for the first seizure, thereby unmasking the genetic seizure predisposition in the children in our cohort. Seizure precipitation by vaccination or fever is a hallmark of *SCN1A*-related Dravet syndrome.<sup>15,30–32</sup> Although fever is a known seizure precipitant in children with a *PCDH19* mutation, a 1q-terminal deletion, and *SCN1A*-related GEFS+ syndrome,<sup>33–36</sup> our study is the first to acknowledge vaccination-related onset in the latter 3 syndromes. A chance association is unlikely because vaccination-related seizures recurred after a second vaccination in both the GEFS+ and 1qter case, occurred in an additional case of *SCN1A*-related GEFS+ syndrome with only febrile seizures (Table 1), and have previously been reported in another girl with a *PCDH19* mutation<sup>19</sup> and 2 GEFS+ cases.<sup>37</sup>

The majority of children with vaccination-related onset of epilepsy in our study were reported to have fever-sensitive

epilepsy at follow-up. Interestingly, these children more often had vaccination-related seizures with body temperature <38.5°C, which was significantly lower than in all other children, confirming previous observations in patients with Dravet syndrome.<sup>17</sup> In this study, we found that significance is sustained after exclusion of children diagnosed with Dravet syndrome (data not shown), suggesting that many children with vaccination-related epilepsy onset have an increased sensitivity to even mild body temperature elevations.

One-quarter of our cases with vaccination-related epilepsy onset had seizures reported after subsequent vaccinations as well. This finding raises the question as to whether these children should receive further vaccinations. The present study was not designed to test the influence of further vaccinations on disease course. However, a study on Dravet syndrome found no differences in outcome between children who did or did not receive further vaccinations.<sup>15</sup> In the groups of children with presumed preexistent and epileptic encephalopathies, all except one reported seizure occurred after inactivated instead of live attenuated vaccines. Because the estimated increased risks of seizures after both vaccine types are roughly the same,<sup>2</sup> this difference is probably largely explained by the higher number of administered inactivated vaccines (ratio: 4 to 1 live attenuated vaccine) in the first 2 years of life. However, currently, developed countries mainly use less reactogenic acellular pertussis vaccines.<sup>26</sup> Moreover, cancellation of vaccination increases the risk of a vaccine-preventable disease (eg, pertussis, measles). These diseases may also induce seizures or cause other, more severe complications. All these aspects must be taken into account when reviewing current

vaccination guidelines for children with epilepsy.

In our study, approximately one-third of all children with epilepsy with vaccination-related onset had benign epilepsy. This information is important for clinicians and parents because previous studies focused mainly on epileptic encephalopathy with onset after vaccination. This method may have given the false impression that vaccination-related seizure onset in general has a bad prognosis. The proportion of children with benign epilepsy in our study may even be underestimated because we selected a cohort from an enhanced passive reporting system for AEFI. The parents of children with more severe epilepsies may be more likely to consider vaccinations causative of the epilepsy and more willing to report seizures as an AEFI.<sup>38,39</sup> Because the time interval between the first seizure and the diagnosis of epilepsy is probably longer, and our initial follow-up period was limited, a diagnosis may not have been made within the follow-up period and thus have led to an underestimation of the proportion of benign epilepsy in our study. However, the Dutch vaccine adverse event surveillance system has a very high reporting rate, with limited underreporting of severe adverse events such as seizures.<sup>25,26</sup> Further bias toward a specific subgroup is probably limited because of the high response rate, long prospective follow-up, similar length of initial follow-up, and similar delay in reporting the vaccination-related seizure in the 3 subgroups of epilepsy with vaccination-related onset.

We confirm the high proportion of children with *SCN1A*-related Dravet syndrome (8 of 12 cases within the subgroup of patients with epileptic encephalopathy) that was previously described.<sup>10</sup> In our study,

**TABLE 3** Characteristics of Epilepsy and Development and Underlying Causes in Children With Vaccination-Related Epilepsy Onset, At Stage 2 Follow-up


| No.  | Gender | Age at Vaccination (mon) | Reported Vaccinations | Seizure Classification | Fever sensitivity | Electroclinical Syndromes                                  | Outcome | Etiology                      |
|--|--------|--------------------------|-----------------------|------------------------|-------------------|--|---------|-------------------------------|
| Group I: Presumed preexistent encephalopathy |        |                          |                       |                        |                   |  |         |                               |
| 1  | Female | 6.4                      | dh3, 4                | GTCS SE At F           | +                 | Epilepsy due to chromosomal disorder                       | I       | Genetic; 1qter deletion       |
| 2  | Male   | 5.6                      | dh3                   | F GTCS                 | +                 | Epilepsy due to neuronal migration disorder                | C       | Structural; BPNH              |
| 3  | Female | 15.2                     | MMR                   | F                      | +                 | Unclassified epilepsy                                      | I       | Unknown                       |
| Group II: epileptic encephalopathy           |        |                          |                       |                        |                   |  |         |                               |
| 4  | Female | 3.9                      | dh2, 4                | GTCS F SE M A H At     | +                 | Dravet syndrome  | I       | Genetic; <i>SCN1A</i>         |
| 5  | Female | 3.4                      | dh1, 2, 3             | GTCS H F A M           | +                 | Dravet syndrome  | I       | Genetic; <i>SCN1A</i>         |
| 6  | Male   | 4.4                      | d2                    | GTCS H A M             | +                 | Dravet syndrome  | I       | Genetic; <i>SCN1A</i>         |
| 7  | Male   | 5.2                      | dh3                   | GTCS H SE F A M        | +                 | Dravet syndrome  | I       | Genetic; <i>SCN1A</i>         |
| 8  | Male   | 4.8                      | dh3                   | GTCS H T SE M F A      | +                 | Dravet syndrome  | I       | Genetic; <i>SCN1A</i>         |
| 9  | Male   | 4.9                      | dh2                   | GTCS H SE M F          | +                 | Dravet syndrome  | I       | Genetic; <i>SCN1A</i>         |
| 10   | Female | 4.6                      | dh3                   | GTCS At F SE           | +                 | Dravet syndrome  | C       | Genetic; <i>SCN1A</i>         |
| 11   | Male   | 4.4                      | dh3, 4                | GTCS M At A SE         | +                 | Dravet syndrome  | I       | Genetic; <i>SCN1A</i>         |
| 12   | Female | 12.1                     | dh4                   | GTCS H T M A           | +                 | Epilepsy and mental retardation limited to female subjects | I       | Genetic; <i>PCDH19</i>        |
| 13   | Female | 2.3                      | dh1, 2                | F GTCS SE              | +                 | Epilepsy due to neuronal migration disorder                | Died    | Structural; BPSMD (pathology) |
| 14   | Female | 6.4                      | dh3                   | GTCS SE F              | +                 | Unclassified epilepsy                                      | C       | Unknown                       |
| 15   | Female | 5.3                      | dh3                   | IS, F GTCS M A At      | -                 | West syndrome; Lennox-Gastaut                              | I       | Unknown                       |
| Group III: epilepsy with good outcome        |        |                          |                       |                        |                   |  |         |                               |
| 16   | Female | 13.0                     | dh4, MMR              | GTCS F                 | +                 | Febrile seizures plus                                      | SF      | Genetic; <i>SCN1A</i>         |
| 17   | Female | 4.7                      | dh3                   | F                      | -                 | Unclassified, familial epilepsy                            | SF      | Genetic; ND                   |
| 18   | Male   | 5.5                      | dh3                   | GTCS                   | -                 | Benign familial infantile epilepsy                         | SF      | Genetic; ND                   |
| 19   | Female | 11.2                     | dh4                   | GTCS A SE              | +                 | Febrile seizures plus                                      | C       | Unknown                       |
| 20   | Male   | 14.5                     | mc <sup>c</sup>       | F A                    | +                 | Febrile seizures plus                                      | SF      | Unknown                       |
| 21   | Female | 14.3                     | MMR                   | GTCS SE                | +                 | Febrile seizures plus                                      | SF      | Unknown                       |
| 22   | Male   | 16.2                     | MMR                   | GTCS F A               | +                 | Febrile seizures plus                                      | SF      | Unknown                       |
| 23   | Male   | 14.6                     | mc                    | F                      | -                 | Unclassified   | SF      | Unknown                       |

A, absence; At, atonic; BPNH, bilateral periventricular nodular heterotopias; BPSMD, bilateral perisylvian migration disorder; C, controlled with antiepileptic drugs; CT, computed tomography; d = diphtheria, tetanus, whole-cell pertussis, inactivated polio vaccine; DD, developmental delay; DN, de novo; F, focal seizure; GTCS, generalized tonic-clonic seizure; h, *Haemophilus influenzae* type b; H, hemiconvulsion; I, intractable; IS, infantile spasms; ND, not determined; M, myoclonia; mc, MMR and meningococcal serogroup C; NA, not available; P, paternal; SE, status epilepticus; SF, seizure free; T, generalized tonic seizure.

<sup>a</sup> Congenital malformations and dysmorphic features.

<sup>b</sup> First- or second-degree relative with febrile seizures or epilepsy.

<sup>c</sup> Seizure categorized as temporally related to meningitis C vaccination because of 13-hour interval.



**FIGURE 2**

Family pedigrees. A, Case 17 with unclassified epilepsy. B, Case 18 with benign familial infantile epilepsy. The inheritance pattern of epilepsy was compatible with autosomal dominant transmission in both families.

West syndrome was a much less frequently identified epilepsy syndrome after vaccination, in contrast to another study,<sup>18</sup> probably because we used strict criteria for a temporal relation between vaccination and seizures.

## CONCLUSIONS

In our cohort, underlying genetic or structural causes were identified in 65% of children with epilepsy with vaccination-related onset. These underlying causes were not limited to *SCN1A*-related Dravet syndrome but extended to other genetically determined fever-sensitive epilepsies. In addition, one-third of cases had

| Inheritance | CT/MRI scan of brain          | Preexistent DD | Developmental Delay | Intellectual Disability | Malformations <sup>a</sup> | Molecular Testing | Family History <sup>b</sup> |
|-------------|-------------------------------|----------------|---------------------|-------------------------|----------------------------|-------------------|-----------------------------|
| DN          | Atrophic cortex               | +              | +                   | +                       | +                          | +                 | –                           |
|             | BPNH                          | ?              | +                   | +                       | +                          | +                 | –                           |
|             | White matter lesions          | +              | +                   | +                       | –                          | –                 | –                           |
| DN          | Normal                        | –              | +                   | +                       | –                          | +                 | +                           |
| DN          | Normal                        | –              | +                   | +                       | –                          | +                 | +                           |
| DN          | Normal                        | –              | +                   | +                       | –                          | +                 | –                           |
| DN          | Aspecific                     | –              | +                   | +                       | –                          | +                 | +                           |
| ND          | Aspecific                     | –              | +                   | +                       | –                          | +                 | +                           |
| DN          | Normal                        | –              | +                   | +                       | –                          | +                 | –                           |
| DN          | Mild atrophy                  | –              | +                   | +                       | –                          | +                 | –                           |
| DN          | Normal                        | –              | +                   | +/–                     | –                          | +                 | –                           |
| DN          | Normal                        | –              | +                   | +                       | –                          | +                 | –                           |
|             | Atrophy, white matter lesions | ?              | +                   | NA                      | +                          | –                 | –                           |
|             | Arachnoid cyst                | –              | +                   | +                       | –                          | +                 | –                           |
|             | Normal                        | –              | +                   | +                       | –                          | +                 | –                           |
|             | P                             | NA             | –                   | –                       | –                          | +                 | +                           |
|             | Normal                        | –              | +                   | –                       | –                          | –                 | +                           |
|             | NA                            | –              | –                   | –                       | –                          | –                 | +                           |
|             | NA                            | –              | –                   | –                       | –                          | –                 | –                           |
|             | Normal (CT)                   | –              | –                   | –                       | –                          | –                 | –                           |
|             | Normal                        | –              | –                   | –                       | –                          | –                 | +                           |
|             | NA                            | –              | –                   | –                       | –                          | –                 | –                           |

relatively benign epilepsy with good outcome, showing that vaccination-related epilepsy onset does not necessarily have a poor prognosis. These results imply that early genet-

ic testing should be considered in all children with vaccination-related onset of epilepsy and might help to support public faith in vaccination programs.

## ACKNOWLEDGMENTS

We thank all parents who gave consent for the study and all general practitioners and attending physicians for providing clinical data.

## REFERENCES

1. Gangarosa EJ, Galazka AM, Wolfe CR, et al. Impact of anti-vaccine movements on pertussis control: the untold story. *Lancet*. 1998;351(9099):356–361
2. Barlow WE, Davis RL, Glasser JW, et al; Centers for Disease Control and Prevention Vaccine Safety Datalink Working Group. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. *N Engl J Med*. 2001;345(9):656–661
3. Moore DL, Le Saux N, Scheifele D, Halperin SA; Members of the Canadian Paediatric Society/Health Canada Immunization Monitoring Program Active (IMPACT). Lack of evidence of encephalopathy related to pertussis vaccine: active surveillance by IMPACT, Canada, 1993–2002. *Pediatr Infect Dis J*. 2004;23(6):568–571
4. Ray P, Hayward J, Michelson D, et al; Vaccine Safety Datalink Group. Encephalopathy after whole-cell pertussis or measles vaccination: lack of evidence for a causal association in a retrospective case-control study. *Pediatr Infect Dis J*. 2006;25(9):768–773
5. Ward KN, Bryant NJ, Andrews NJ, et al. Risk of serious neurologic disease after immunization of young children in Britain and Ireland. *Pediatrics*. 2007;120(2):314–321
6. Sun Y, Christensen J, Hviid A, et al. Risk of febrile seizures and epilepsy after vaccination with diphtheria, tetanus, acellular pertussis, inactivated poliovirus, and Haemophilus influenzae type B. *JAMA*. 2012;307(8):823–831
7. Griffin MR, Ray WA, Mortimer EA, Fenichel GM, Schaffner W. Risk of seizures after measles-mumps-rubella immunization. *Pediatrics*. 1991;88(5):881–885
8. Vestergaard M, Hviid A, Madsen KM, et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. *JAMA*. 2004;292(3):351–357
9. Strebel PM, Papania MJ, Parker Fiebelkorn A, Halsey NA. Measles vaccine. In: Plotkin SA, Orenstein WA, Offit PA, eds. *Vaccines*. 6th ed. Philadelphia, PA: Elsevier; 2012:352–387
10. Berkovic SF, Harkin L, McMahon JM, et al. De-novo mutations of the sodium channel gene SCN1A in alleged vaccine encephalopathy: a retrospective study. *Lancet Neurol*. 2006;5(6):488–492



11. Dravet C. The core Dravet syndrome phenotype. *Epilepsia*. 2011;52(suppl 2):3–9
12. Depienne C, Trouillard O, Saint-Martin C, et al. Spectrum of SCN1A gene mutations associated with Dravet syndrome: analysis of 333 patients. *J Med Genet*. 2009;46(3):183–191
13. Depienne C, Trouillard O, Gourfinkel-An I, et al. Mechanisms for variable expressivity of inherited SCN1A mutations causing Dravet syndrome. *J Med Genet*. 2010;47(6):404–410
14. Mulley JC, Scheffer IE, Petrou S, Dibbens LM, Berkovic SF, Harkin LA. SCN1A mutations and epilepsy. *Hum Mutat*. 2005;25(6):535–542
15. McIntosh AM, McMahon J, Dibbens LM, et al. Effects of vaccination on onset and outcome of Dravet syndrome: a retrospective study. *Lancet Neurol*. 2010;9(6):592–598
16. Reyes IS, Hsieh DT, Laux LC, Wilfong AA. Alleged cases of vaccine encephalopathy re-diagnosed years later as Dravet syndrome. *Pediatrics*. 2011;128(3). Available at: [www.pediatrics.org/cgi/content/full/128/3/e699](http://www.pediatrics.org/cgi/content/full/128/3/e699)
17. Verbeek NE, van der Maas NA, Jansen FE, van Kempen MJ, Lindhout D, Brillstra EH. Prevalence of SCN1A-related dravet syndrome among children reported with seizures following vaccination: a population-based ten-year cohort study. *PLoS One*. 2013;8(6):e65758
18. von Spiczak S, Helbig I, Drechsel-Baeuerle U, et al. A retrospective population-based study on seizures related to childhood vaccination. *Epilepsia*. 2011;52(8):1506–1512
19. Jamal SM, Basran RK, Newton S, Wang Z, Milunsky JM. Novel de novo PCDH19 mutations in three unrelated females with epilepsy female restricted mental retardation syndrome. *Am J Med Genet A*. 2010;152A(10):2475–2481
20. Novy J, Catarino CB, Chinthapalli K, et al. Another cause of vaccine encephalopathy: a case of Angelman syndrome. *Eur J Med Genet*. 2012;55(5):338–341
21. Vermeer-de Bondt PE, Moorers-Lanser N, Phaff TA, Oostvogels B, Wesselo C, van der Maas NA. Adverse events in the Netherlands vaccination programme: reports in 2010 and review 1994-2010. RIVM, Bilthoven 2011;205051004. Available at: [http://www.rivm.nl/en/Documents\\_and\\_publications/](http://www.rivm.nl/en/Documents_and_publications/)
22. Farrington P, Pugh S, Colville A, et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. *Lancet*. 1995;345(8949):567–569
23. Jacobsen SJ, Ackerson BK, Sy LS, Tran TN, Jones TL, Yao JF, Xie F, Cheetham TC, Saddier P. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. *Vaccine*. 2009;27(34):4656–4661
24. van der Maas NA, Phaff TAJ, Wesselo C, Vermeer-de Bondt PE. Adverse events following immunizations under the national vaccination programme of the Netherlands. Number XIII-reports in 2006. RIVM, Bilthoven 2007;240071004. Available at: [http://www.rivm.nl/en/Documents\\_and\\_publications/](http://www.rivm.nl/en/Documents_and_publications/)
25. Vermeer-de Bondt PE, Moorers-Lanser N, Phaff TAJ, Oostvogels B, Wesselo C, Maas van der NAT. Adverse events in the Netherlands Vaccination Programme; reports in 2010 and review 1994-2010. RIVM, Bilthoven 2011, 205051004. Available at: [http://www.rivm.nl/en/Documents\\_and\\_publications/](http://www.rivm.nl/en/Documents_and_publications/)
26. David S, Vermeer-de Bondt PE, van der Maas NA. Reactogenicity of infant whole cell pertussis combination vaccine compared with acellular pertussis vaccines with or without simultaneous pneumococcal vaccine in the Netherlands. *Vaccine*. 2008;26(46):5883–5887
27. Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. *Epilepsia*. 2010;51(4):676–685
28. van Harssel JJ, Weckhuysen S, van Kempen MJ, et al. Clinical and genetic aspects of PCDH19-related epilepsy syndromes and the possible role of PCDH19 mutations in males with autism spectrum disorders. *Neurogenetics*. 2013;14(1):23–34
29. Volkers L, Kahlig KM, Verbeek NE, et al. Nav 1.1 dysfunction in genetic epilepsy with febrile seizures-plus or Dravet syndrome. *Eur J Neurosci*. 2011;34(8):1268–1275
30. Caraballo RH, Fejerman N. Dravet syndrome: a study of 53 patients. *Epilepsy Res*. 2006;70(suppl 1):S231–S238
31. Nieto-Barrera M, Lillo MM, Rodríguez-Collado C, Candau R, Correa A. Severe myoclonic epilepsy in childhood. Epidemiologic analytical study [in Spanish]. *Rev Neurol*. 2000;30(7):620–624
32. Tro-Baumann B, von Spiczak S, Lotte J, et al. A retrospective study of the relation between vaccination and occurrence of seizures in dravet syndrome. *Epilepsia*. 2011;52(1):175–178
33. Depienne C, Bouteiller D, Keren B, et al. Sporadic infantile epileptic encephalopathy caused by mutations in PCDH19 resembles Dravet syndrome but mainly affects females. *PLoS Genet*. 2009;5(2):e1000381
34. Scheffer IE, Berkovic SF. Generalized epilepsy with febrile seizures plus. A genetic disorder with heterogeneous clinical phenotypes. *Brain*. 1997;120(pt 3):479–490
35. van Bon BW, Koolen DA, Borgatti R, et al. Clinical and molecular characteristics of 1qter microdeletion syndrome: delineating a critical region for corpus callosum agenesis/hypogenesis. *J Med Genet*. 2008;45(6):346–354
36. Wallace RH, Scheffer IE, Barnett S, et al. Neuronal sodium-channel alpha1-subunit mutations in generalized epilepsy with febrile seizures plus. *Am J Hum Genet*. 2001;68(4):859–865
37. Zamponi N, Passamonti C, Petrelli C, et al. Vaccination and occurrence of seizures in SCN1A mutation-positive patients: a multicenter Italian study. *Pediatr Neurol*. 2014;50(3):228–232
38. Hasford J, Goettler M, Munter KH, Müller-Oerlinghausen B. Physicians' knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions. *J Clin Epidemiol*. 2002;55(9):945–950
39. Rosenthal S, Chen R. The reporting sensitivities of two passive surveillance systems for vaccine adverse events. *Am J Public Health*. 1995;85(12):1706–1709

(Continued from first page)

**FINANCIAL DISCLOSURE:** The authors have indicated they have no financial relationships relevant to this article to disclose.

**FUNDING:** Dr Verbeek was supported by the "Stichting Vrienden UMC Utrecht" (project 10.053; [www.vriendenumcutrecht.nl](http://www.vriendenumcutrecht.nl)) on behalf of the Janivo Stichting and by the NutsOhra Fund (grant 0801-064; [www.fondsnutsohra.nl](http://www.fondsnutsohra.nl)).

**POTENTIAL CONFLICT OF INTEREST:** The authors have indicated they have no potential conflicts of interest to disclose.

## Etiologies for Seizures Around the Time of Vaccination

Nienke E. Verbeek, Floor E. Jansen, Patricia E. Vermeer-de Bondt, Carolien G. de Kovel, Marjan J.A. van Kempen, Dick Lindhout, Nine V.A.M. Knoers, Nicoline A.T. van der Maas and Eva H. Brilstra

*Pediatrics* originally published online September 15, 2014;

|   |  |
|---|--|
| <b>Updated Information &amp; Services</b> | including high resolution figures, can be found at:<br><a href="http://pediatrics.aappublications.org/content/early/2014/09/09/peds.2014-0690">http://pediatrics.aappublications.org/content/early/2014/09/09/peds.2014-0690</a>                   |
| <b>Supplementary Material</b>             | Supplementary material can be found at:<br><a href="http://pediatrics.aappublications.org/content/suppl/2014/09/09/peds.2014-0690.DCSupplemental">http://pediatrics.aappublications.org/content/suppl/2014/09/09/peds.2014-0690.DCSupplemental</a> |
| <b>Permissions &amp; Licensing</b>        | Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:<br><a href="https://shop.aap.org/licensing-permissions/">https://shop.aap.org/licensing-permissions/</a>                          |
| <b>Reprints</b>                           | Information about ordering reprints can be found online:<br><a href="http://classic.pediatrics.aappublications.org/content/reprints">http://classic.pediatrics.aappublications.org/content/reprints</a>  |

Pediatrics is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since . Pediatrics is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2014 by the American Academy of Pediatrics. All rights reserved. Print ISSN: .

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™



# PEDIATRICS®

OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF PEDIATRICS

## **Etiologies for Seizures Around the Time of Vaccination**

Nienke E. Verbeek, Floor E. Jansen, Patricia E. Vermeer-de Bondt, Carolien G. de Kovel, Marjan J.A. van Kempen, Dick Lindhout, Nine V.A.M. Knoers, Nicoline A.T. van der Maas and Eva H. Brilstra

*Pediatrics* originally published online September 15, 2014;

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://pediatrics.aappublications.org/content/early/2014/09/09/peds.2014-0690>

Pediatrics is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since . Pediatrics is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2014 by the American Academy of Pediatrics. All rights reserved. Print ISSN: .

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™

